HBV has evolved a unique life cycle that results in the production of enormous viral loads during active replication without actually killing the infected cells directly. Two of the key events in the viral life cycle of HBV involve firstly the generation of a covalently closed circular (ccc) DNA transcriptional template, either from input genomic DNA or newly replicated capsid-associated DNA, and secondly, reverse transcription of the viral pregenomic (pg) RNA to form progeny HBV DNA genomes. New data are emerging regarding the epigenetic control of cccDNA, which might represent another key factor involved in the pathogenesis and natural history of the disease. Because HBV uses reverse transcription to copy its genome, mutant viral genomes emerge frequently. Particular selection pressures, both endogenous (host immune clearance) and exogenous (vaccines and antiviral drugs), readily select out these escape mutants. The particular viral mutations or combination of mutations that directly affect the clinical outcome of infection are not known; however, four major 'pathways' of antiviral drug resistance-associated substitutions have now been identified. Further studies are clearly needed to identify the pathogenetic basis and clinical sequelae arising from the selection of these particular mutants. In the clinical context of antiviral drug resistance, treating physicians need to adopt therapeutic strategies that effectively control viral replication. Finally, the role of host genetics in influencing the outcome of HBV disease in the context of natural history and therapy is beginning to aid understanding in pathogenesis and, when this knowledge is linked to pathogen-specific databases, this should translate into more individualized patient care.
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The major route of transmission of HBV is perinatally from hepatitis B e antigen (HBeAg)-positive chronically infected mothers (typically in the Asia-Pacific region) or via early horizontal transmission from close contact (typically in the Mediterranean region and Africa) with immediate family members [1] . This virus can also be spread by sexual contact, following inoculation with contaminated blood or blood products, or by transplantation of organs from infected donors. Serum HBV DNA is considered a reliable indicator of active infection and hepatitis B surface antigen (HBsAg) a marker of chronic hepatitis B (CHB) carriage [1] . The risk of transmission from infected individuals, however, is unpredictable because of the substantial variability in HBV replicative activity that occurs during the various phases of CHB infection [2] . Nonetheless, the presence of HBsAg is still regarded as the most important marker of infectivity, irrespective of viral load. Likewise, the outcome of interventions with specific antiviral therapy is also often unpredictable, but recent progress in human genome-wide associations is providing new insights into host-pathogen relationships [3] . This article reviews the unique process of HBV genomic replication, including common viral mutations that influence expression of its major proteins and the development of antiviral drug resistance. Furthermore, the clinical significance of these drug-resistant mutations is not just treatment failure, but can also have potentially serious implications for the patient's well-being in the medium to long term.
Introduction
strategy of genome replication [4] . The HBV genome is a relatively small partially double-stranded relaxed circular (RC) DNA of 3,200 base pairs, consisting of a full-length minus strand DNA with a terminal redundancy of 7-9 nucleotides (nt) and an incomplete plus strand of variable length ( Figure 1 ). All the recognized coding information is on the minusstrand and is organized into four open reading frames (ORF). The longest ORF encodes the viral polymerase (Pol; Pol-ORF). The envelope ORF is located within the Pol-ORF but in a frame-shifted manner. Partially overlapping with the envelope ORF are the core (C) and the X ORFs ( Figure 1 ).
Viral life cycle
Early events of the viral life cycle include attachment, penetration and uncoating. The first stage of infection is attachment of the virus to a susceptible hepatocyte and penetration of HBV into the cell cytoplasm following the binding of the HBV envelope to its specific cellular receptor or coreceptor. Most studies of HBV have shown that the Pre-S1 domain is required for receptor binding and initiation of infection [4] . Following penetration, viral cores disassemble and genomic DNA is transported to the cell nucleus [5, 6] . This transport is mediated by a nuclear localization signal on the capsid The HBV genome is a 3.2 kb double-stranded DNA molecule that is organized into four open reading frames: the polymerase, the envelope, the precore and X. The HBV genome is also highlighted, showing the relevance of the overlap between the polymerase and envelope, so that mutations in one reading frame can affect the other. This means that drug-resistant HBV typically has an altered viral envelope of hepatitis B surface antigen. DR, direct repeat.
protein and the encapsidated HBV genome gains access to the nucleus via the importin pathway using nuclear transport receptors Imp-β/Imp-α. Inside the nucleus, the capsid dissociates and the genomic RC DNA is converted by host cell DNA repair enzymes to a covalently closed circular (ccc)DNA molecule. The cccDNA is found as a viral minichromosome [7, 8] and acts as the major transcriptional template for the virus (Figure 2) .
The life cycle of HBV revolves around two key processes: generation of HBV cccDNA from the RC DNA and its subsequent processing by host enzymes to produce viral RNA; and reverse transcription of the pregenomic (pg)RNA within the viral nucleocapsid to form RC DNA, completing the cycle (Figure 2 ). The first key step in HBV replication is the conversion of genomic RC DNA into cccDNA and transcription of the viral minichromosome. Formation of HBV cccDNA defines successful infection of a cell. At least four steps are involved in the conversion of genomic RC DNA to cccDNA: repair of the single-stranded gap region; removal of the 5′-terminal structures, including the capped oligoribonucleotide on the plus strand and HBV Pol protein on the minus strand; removal of the short terminal redundancy of the minus strand; and covalent ligation of both strands, thus forming cccDNA. The HBV core protein is a structural component of the viral minichromosome and its specific binding results in a reduction of the nucleosomal spacing of the HBV nucleoprotein complexes [9] . Pollicino et al. [10] have demonstrated that HBV replication is regulated by the acetylation status of H3/H4 histones bound to the viral cccDNA, and that nuclear hepatitis B X protein binds to the HBV minichromosome and modifies the epigenetic regulation of cccDNA function [11] . Four major RNA species: the 3.5, 2.4, 2.1 and 0.7 kb viral RNA transcripts [4] are produced from this viral minichromosome. Expression of these four transcripts is directed by the enhancer II/basal core, large surface proteins, middle surface proteins and enhancer I/X gene promoters, respectively [4] . These RNAs are then transported to and translated in the cytoplasm to produce the viral proteins, namely hepatitis B core antigen (HBcAg) or nucleocapsid protein, from the 3.5 kb pgRNA; the soluble and secreted HBeAg (from the 3.5 kb precore messenger RNA); the Pol protein (from the 3.5 kb pgRNA); the viral envelope proteins, which express HBsAg (from the 2.4 and 2.1 kb RNAs); and the hepatitis B X protein (from the 0.7 kb RNA). In addition to serving as messenger RNA for the nucleocapsid and Pol proteins, the 3.5 kb pgRNA acts as the template for reverse transcription of the viral genome ( Figure 2 ) [12] . Thus, two classes of transcript are synthesized from the HBV minichromosome: greater than genomic length and subgenomic length [4] . Both classes contain heterogeneous transcripts that are of positive orientation, are capped at the 5′-end and are polyadenylated at the 3′-end.
The second key step is HBV genomic DNA replication via reverse transcription. HBV genomic replication is initiated with packaging of the pgRNA and the viral reverse transcriptase into subviral core particles, forming cytoplasmic replication complexes. Reverse transcription occurs within the HBV nucleocapsid. As the HBV Pol is being translated from the pgRNA molecule, the N-terminal region (terminal protein) binds to a unique RNA stem loop structure, known as e, at the 5′-end of the pgRNA [13] . The HBV Pol undergoes a conformational change, which results in enzymatic activation. This packaged pol uses the hydroxyl group of the tyrosine residue at amino acid 63 within the terminal protein domain to prime DNA synthesis [14] . This Pol-oligonucleotide complex is then translocated to the complementary sequences of a direct repeat (DR)-1 region located at the 3′ end of the pgRNA. From here, minus strand DNA synthesis continues until it reaches the 5′-end of the pgRNA molecule [15] , generating a short terminal redundancy of 8-9 nt. While reverse transcription is proceeding, the pgRNA is degraded by the RNaseH activity of the HBV Pol, except for the 5′ capped terminal 18 nt that contains the DR-1 sequence [4] . This fragment includes a 6 nt homology to the DR sequence. The 18 nt capped RNA structure is then translocated to a second DR sequence (DR-2) on the 5′-end of the newly made minus strand DNA, where it acts as a primer for plus strand synthesis, using the minus strand as the template [15] . Synthesis of the plus strand DNA continues until it reaches approximately 50-70% of the length of the minus strand.
The late events in viral replication include viral assembly and release. The assembly of nucleocapsids containing mature RC DNA occurs in the cytosol [16] . Those nucleocapsids are selectively enveloped prior to leaving the cell. Immature nucleocapsids containing pgRNA are incompetent for envelopment, which can occur only after initiation of reverse transcription [4] . Synthesis of the minus strand DNA appears to be coupled to phosphorylation of the nucleocapsid, which is required for envelopment to occur. Correct assembly of replicating cores with the viral envelopes requires a crucial relative molar ratio of Pre-S1 to S, whereby insufficient S or excessive Pre-S1 production results in abnormal assembly and release [4] .
The viral envelope components, including the small particles and the filaments, are synthesized and assembled at the endoplasmic reticulum membranes and then bud into its lumen. The Pre-S1, Pre-S2 and S proteins have different but essential functions during morphogenesis. These different functions appear to be related to their transmembrane topology [16] . The topology of the Pre-S2 and S proteins is determined by at least two signal sequences, resulting in a short luminal exposed N-terminal sequence, two transmembrane regions separated by a 55-amino-acid cytosolic loop and a luminal 70-amino-acid domain containing the major epitope of the protein and a glycosylation site [16] . By contrast, the entire Pre-S domain of Pre-S1 remains in the cytosol following translation. During virion maturation, the Pre-S domains reconfigure in approximately 50% of the Pre-S1 molecules, translocating to the surface of the particle. Half of the Pre-S domains remain on the cytosolic side, which, after budding into the endoplasmic reticulum, becomes the internal side of the particle [16] . This dual topology allows the Pre-S1 domain to be externally localized on the virion, where it acts as the attachment-binding protein for the cellular receptor. The Pre-S1 domain also needs to remain on the cytosolic side to play its role in the envelopment of the replicating core particles [16] . Enveloped nucleocapsids are thus deposited into the lumen of the endoplasmic reticulum, after which they move through the Golgi apparatus. The viral particles are secreted from the cell via the constitutive secretory pathway [17] (Figure 2 ).
Common escape mutants of HBV of clinical relevance
The evolution of RNA viruses is typically driven by three main factors: high mutation rates; very short replication times; and generation of very large populations of progeny particles [18] . In addition to viral and host factors, exogenous selection pressures define the predominant HBV species in an infected individual. Exogenous pressures include treatment with nucleoside/nucleotide analogues (NAs) as well as immune-based interventions, such as hepatitis B immunoglobulin (HBIg) and vaccination.
Viral reverse transcriptases lack a proofreading function and are thus inherently error prone. As a result, HBV populations exist in the host as heterogeneous mixtures known as quasispecies. The frequency of HBV mutation has been estimated to be approximately 1.4-3.2×10 -5 nt substitutions per site per year [19] , approximately 10-fold higher than that of other DNA viruses. The magnitude and rate of virus replication are also important in the process of mutation generation; the total viral load in serum frequently approaches ≥10 8 -10
9 virions/ml of plasma in chronically infected patients. Most estimates place the mean half-life of the serum HBV pool at approximately <1 day, translating to a rate of de novo HBV production approaching 10 11 virions/day. The high viral loads and turnover rates coupled with poor replication fidelity influence mutation generation and the complexity of the HBV quasispecies pool. Because of the constraints imposed by the overlapping reading frames (Figure 1 ), the number of fit mutant progeny HBVs is significantly reduced.
Mutations in the envelope gene: diagnostic and vaccine escape
The Pre-S sequences exhibit the highest heterogeneity of the HBV genome [20] . Point mutations, deletions, and genetic recombinations within the Pre-S genes have been identified in HBV DNA sequences obtained from the sera of patients with CHB. HBV genomes that cannot synthesize Pre-S2 proteins occur frequently and are the dominant virus populations in many patients [20] . The Pre-S2 region overlaps the spacer region of the Pol protein, which is not essential for enzyme activity ( Figure 1 ).
Most hepatitis B vaccines contain the major HBsAg protein and induce an immune response to the major hydrophilic region, located from residue 99 to 170, also known as the 'a' determinant. This antibody against HBsAg (anti-HBs) response produces protective immunity. Mutations within this epitope have been selected during vaccination [21] and after treatment of liver allograft recipients with HBIg [22] . Most isolates contain a mutation from glycine to arginine at residue 145 of HBsAg (sG145R) and the sG145R substitution has been associated with vaccine failure [21] . Other mutations have been observed in the HBV genome from patients with viral escape to anti-HBs response.
Mutations affecting the production of HBeAg
These mutations are discussed in detail in the reviews by Gunther et al. [20] and Harrison [23] .
Polymerase mutations: antiviral drug resistance
The advent of treatment with NAs has resulted in the outgrowth of otherwise minor quasispecies containing mutations in the HBV polymerase gene. At present, in most parts of the world, five NAs have been approved for treatment of CHB and within this class of drugs, three structural groups can be identified: the l-nucleosides lamivudine (3TC) and telbivudine (LdT); the acyclic phosphonates adefovir (ADV) and tenofovir disoproxil fumarate (TDF); and the d-cyclopentane NA entecavir (ETV). This is a useful classification of the HBV-specific NAs, as antiviral drug resistance tends to be structure (sugar residue) specific, providing a framework, or 'pathway' concept for understanding resistance selection and patterns of cross-resistance [24] . According to agreed nomenclature [25] , the mutations within the reverse transcriptase (rt) gene that were selected during 3TC therapy, for example, are designated as rtM204I/V/S (domain C) with or without rtL180M (domain B) [25] .
l-Nucleoside resistance 3TC resistance increases progressively during treatment at rates between 14% and 32% annually, approaching 70% after 48 months of treatment [26] . Factors that increase the risk of resistance include high pretherapy serum HBV DNA and alanine aminotransferase levels and incomplete suppression of viral replication [26, 27] . 3TC resistance results in cross-resistance to LdT and partial cross-resistance to ETV (Table 1) , but does not confer cross-resistance to TDF. Cross-resistance to ADV might be observed depending on the mutation profile ( Table 1 ).
Mutations that confer 3TC resistance typically map to the catalytic or C domain (YMDD locus) of HBV Pol and are identified by the substitutions rtM204V/I/S (Figure 3) . The l-nucleoside-associated substitutions cause a decrease in the in vitro sensitivity to the NA of >100-fold. The rtM204I substitution has been detected in isolation, but rtM204V and rtM204S are found only in association with other changes in the B (rtL180M) or A (rtL80I/V) motifs. In a minority (<5%) of cases, l-nucleoside analogue drug failure is caused by the emergence of rtA181T/V. Numerous other secondary changes in the rt sequence have also been found to occur in conjunction with rtM204V/I/S [28] , and some of these are probably compensatory. The substitutions rtM204V/I/S do not confer cross-resistance to ADV or TDF, whereas rtA181T does. The rtM204V/I substitutions result in a HBV Pol that is partially crossresistant with ETV.
Acyclic phosphonate resistance HBV resistance to ADV occurs less frequently (approximately 2% after 2 years) compared with 3TC, but then rises steadily to 30% by 5 years. ADV resistance is conferred by substitution of threonine for asparagine at codon 236 (Figure 3) , located in the D motif of HBV (rtN236T) and the B domain mutation rtA181T [29] . The change of rtN236T does not appear to affect sensitivity to 3TC, but the rtA181T does (see l-Nucleoside resistance). These substitutions confer only a modest increase (3-8-fold) in the drug concentration required to inhibit 50% of the viral replication in vitro and are partially cross-resistant to TDF in vitro, but remain sensitive to ETV. Likewise, the rtN236T substitution does not significantly affect sensitivity to 3TC or LdT but the rtA181T change does (Table 1) . Clinically, patients with genotypic 3TC-resistant HBV respond well to TDF [30] , whereas patients with genotypic ADV resistant HBV might respond suboptimally [31] .
d-Cyclopentane resistance
Primary resistance to ETV is uncommon and only approximately 1% of patients show genotypic resistance by 6 years of continuous therapy [24] . Mutations in the viral pol associated with the emergence of ETV resistance have been mapped to domain B (rtI169T or rtT184G), domain C (rtS202I) and domain E (rtM250V) in association with the rtL180M plus rtM204V substitutions involved with l-nucleoside analogue resistance (Figure 3) . Thus, at least three substitutions are required for ETV resistance. HBVs with those ETV-associated substitutions remain sensitive to ADV and TDF, but are completely cross-resistant to any of the l-nucleoside analogues.
Mutational pathways and cross-resistance
From the preceding discussion, it can be seen that only eight codons in HBV Pol are associated with primary drug resistance to all five of the approved NAs: 169, 180, 181, 184, 202, 204, 236, 250. These eight codons have been shown to be involved in HBV antiviral drug resistance via four pathways of viral evolution [32] : the rtM204V/I pathway for l-nucleosides [33] ; the rtN236T pathway for acyclic phosphonates [29, 34] ; the rtA181T/V pathway, which is shared between the l-nucleosides and acyclic phosphonates [35, 36] ; and the d-cyclopentane/ETV pathway (rtL180M plus rtM204V with at least one of rtI169T, rtT184S/G/C, rtS202C/G/I or rtM250I/V) [37, 38] . The first three pathways are associated with only one mutation in the HBV genome, whereas the fourth pathway requires at least three mutations for the emergence of ETV resistance. This 'pathways of evolution' approach should facilitate an understanding of HBV evolution during NA therapy and can be used to predict patient outcomes and improve the understanding of cross-resistance patterns and profiles (Table 1 ) [32] .
Implications of viral heterogeneity on viral fitness
The selection of resistant mutants depends not only on the antiviral pressure exhibited by therapy but also on the capacity of the mutants to emerge and outgrow wild-type viruses. Two main factors are involved: the fitness of the mutants (that is, their capacity to produce progeny virus in the presence of antivirals) and the replication space available in the liver for mutant spread [39, 40] . The accumulation of mutations on the viral genome might result in different virological outcomes: some mutations might be considered as compensatory if they increase the replication capacity of the primary resistance mutation; and some resistance mutation might have a cost on replication capacity leading to less fit mutants. The latter scenario might correspond to Pol mutations associated with decreased enzymatic activity and/or to variants harbouring mutations in the envelope overlapping gene with decreased infectivity [41, 42] . This could be one of the explanations for the increased barrier to resistance of the newer generation of NAs, such as TDF and ETV [24] .
Pathogeneticity of drug resistant HBV

Role of compensatory mutations
Ogata et al. [43] observed the co-occurrence of rtL80V/I (domain A) and rtL180M in conjunction with the M204V/I changes that confer 3TC resistance in Japanese patients (genotype C) treated with 3TC. The presence of double and triple changes has been associated with higher viral loads, increased 3TC resistance and disease exacerbation. Longitudinal studies have shown that the mutations responsible for the sequence changes occurred almost simultaneously, just before viral breakthrough occurred, and also that the mutants were displaced by wild-type genotype C HBV after completion of therapy.
Similar observations have been recorded after liver transplantation among patients in whom life-threatening recurrence of HBV infection developed [44] . HBV isolates from these patients contained compensatory mutations that enhanced their in vitro replication efficiency in the presence of 3TC. Even greater enhancement and drug dependency occurred when mutations resulting in sG145R or sP120T, key changes in the envelope protein, were also present [44] .
Mutations that abolish or decrease the expression of HBeAg are also known to affect replication efficiency. HBeAg-negative CHB, which is most common in the Mediterranean region, is usually characterized by lower serum HBV DNA levels than those found in HBeAgpositive CHB. Hadziyannis et al. [45] and Papatheodoridis et al. [46] studied a group of patients with HBeAgnegative CHB who were infected with HBV genotype D that contained both basal core promoter and precore stop codon mutations. Development of 3TC resistance in these patients was associated with relatively rapid increases in viraemia, culminating frequently in biochemical breakthrough, severe hepatitic flares and disease progression [45, 46] . In vitro studies by Chen et al. [47] confirmed that the presence of the typical precore mutation (G1896A) could compensate for the replication deficiency in 3TC-resistant HBV quasispecies. Other anecdotal reports confirm that drug-resistant HBV mutants are capable of causing severe, even fatal, disease [48] [49] [50] [51] [52] .
Clinical relevance of polymerase-envelope overlap
The pol gene overlaps the envelope gene and, thus, mutations in the overlapping reading frame can cause concomitant changes to both proteins (Figure 1) . The nt change that alters the codon rt204 (rtM204I/V) in the pol gene as a consequence of resistance to 3TC, LdT and ETV, also alters the gene encoding the HBsAg in the overlapping frame-shifted reading frame in the majority of circumstances (>90%). The rtM204V mutation is associated with the mutation sI195M in HBsAg, whereas the rtM204I change is associated with three possible changes: sW196S, sW196L or a termination codon. The rtL180M is silent in HBsAg, but rtV173L results in sE164D and this combination of mutations is found in approximately 20% of cases of 3TC resistance [53, 54] . The ADV resistance mutation rtN236T overlaps with the stop codon at the end of the envelope gene and, therefore, does not affect the translation of that gene. The mutation selected by ADV and/or 3TC/LdT at rtA181T typically results in a stop mutation in the envelope gene (sW172stop), and the ADV-resistance mutation at rtA181V results in a concomitant change at sL173F. Mutations that result in a stop codon mutation in the envelope gene, such as those for 3TC, LdT (rtM204I and rtA181T) and ADV (rtA181T), are present in association with a low percentage of wild-type HBV in order to ensure rescue of viral packaging and release [36] . The ETV resistance mutation at rtI169T results in a change at sF161L. This mutation, as is the sE164D, is located within the 'a' determinant, the antibody neutralization domain of HBV.
Publications documenting transmission of 3TC-resistant HBV between male homosexual partners [55] as well as the observation of 3TC-resistant HBV causing cases of acute hepatitis B in Japan [56] , highlight the importance of drug resistance as an emerging public health issue, and emphasize the need for the establishment of surveillance for drug-resistant virus.
Molecular pathogenesis and oncogenic potential of polymerase-envelope mutants
Several HBV proteins are involved in the development of hepatocellular carcinoma (HCC), transcribed from either integrated HBV DNA or the HBV genome. The HBV surface gene (pre-S1/pre-S2/S) encodes three coterminal surface proteins designated large (L; preS1+pre-S2+S genes), middle (M; pre-S2+S genes) and small (S; S gene). Pre-S2/S genes truncated at the 3′ end (C-terminal) have been isolated from integrated HBV DNA sequences in HCC [57, 58] . The L and M proteins with C-terminal truncations have transcriptional transactivation potential, a function not exhibited by the full-length forms. Truncated HBV surface proteins have been implicated in the progression to HCC as they possess transactivational activity, demonstrated by increased nuclear factor (NF)-κB or activator protein (AP)-1 promoter activity [59] .
Of potential clinical significance is the recent observation that NA therapy selects for HBV mutants that encode truncated surface proteins and therefore could theoretically accelerate the progression to HCC. As discussed above, treatment of CHB with all the NAs can result in the selection of HBV variants with point mutations in the polymerase gene that not only confer NA resistance but also result in changes to HBsAg [36, 60] . In particular, the point mutation that causes the rtA181T change in the polymerase also encodes a stop codon (sW172*) in surface proteins resulting in truncation of the last 55 amino acids of the C-terminal hydrophilic region of the HBsAg. In vitro analysis of rtA181T/sW172* HBV has shown that it is defective in secretion of viral particles resulting in intracellular retention of surface proteins and has a dominant negative effect on wild-type virion secretion resulting in lower viral loads extracellularly [36] . Two recent reports [61, 62] have now provided evidence for involvement of HBV encoding the rtA181T/sW172* mutation in the pathogenesis of and progression to HCC. Analyses of HBV DNA from patients who developed HCC despite 3TC therapy revealed stop codon mutations in the envelope gene in seven of eight patients compared with the control group, in which no patients developed HCC. Using expression constructs encoding the HBV surface proteins, these investigators demonstrated that surface proteins truncated at amino acids sL21, sW156 or sW172 (the latter of which equates to the surface proteins expressed from rtA181T/sW172*) transactivated the c-myc and SV40 promoters. NIH-3T3 cells transfected with these constructs were also tumourigenic when injected into nude mice, whereas the full-length surface proteins were not.
Although NA therapies significantly decrease viral load and improve patient survival in the short term [63] , there appears to be a theoretical risk that such selection of HBV variants with C-terminal truncations might be potentially oncogenic, negating the overall efficacy of NAs in preventing hepatocarcinogenesis, the main long-term goal of antiviral therapy in CHB. Future challenges in the treatment of CHB involve the development of antiviral strategies that effectively inhibit HBV replication eliminating the risk of drug resistance in the first place.
Occult HBV infection
Occult HBV infection (OBI) is defined as the presence of HBV DNA in the liver of individuals testing HBsAgnegative by currently approved diagnostic assays [64] . The patient with OBI may or may not have detectable HBV DNA in serum and when it is found, the amount is usually very low, typically <200 IU/ml. Thus, HBV DNA detection is the only reliable diagnostic marker of OBI. OBI can be further distinguished serologically as either seropositive OBI (antibody against HBcAg and/or anti-HBs positive) or seronegative OBI. In those seropositive OBI individuals, the serum HBsAg could become negative either following the resolution of acute hepatitis B or after years of chronic HBs antigenaemia (reviewed in [64] ). The seronegative OBI cases might have either progressively lost their hepatitis B specific antibodies or have been negative for hepatitis B specific antibody from the beginning of the infection [64] .
As reviewed in Raimondo et al. [64] , the molecular basis for persistent OBI is the long-term stability of HBV cccDNA in the nuclei of infected hepatocytes.
Molecular virological studies have revealed that the majority of cases of OBI are caused by replicationcompetent HBV and only a small number of cases are caused by infection with HBV variants with replication defects or altered HBsAg expression. OBI shows a long-lasting specific T-cell immune response against HBV epitopes [65] .
The pathogenesis of CHB: checks and balances
The HBV is not directly cytopathic to hepatocytes under the usual conditions of chronic infection. The liver damage found in CHB results not directly from viral replication, but instead from the interaction between the host's immune system and HBV-infected hepatocytes. The antiviral cytokines, such as interferon (IFN)-α, -β, -γ and -λ as well as tumour necrosis factor (TNF)-α and other proinflammatory cytokines have all been shown to be the significant contributors to viral clearance, whereas destruction of infected hepatocytes by cytotoxic T-lymphocytes in antiviral models appears to contribute to both viral clearance and the development of liver disease [66] . More recently, the role of the innate immune response is becoming increasingly recognized in the clinical situation with the HBeAg regulating Tolllike receptor 2 expression and signalling [67] .
In patients with self-limited acute HBV infection, viral clearance has been shown to occur via a polyclonal and multispecific peripheral blood mononuclear cell response mounted against particular epitopes of several HBV proteins, including the viral envelope, polymerase and core proteins [68] [69] [70] [71] . This response involves human leukocyte antigen (HLA) class-IIrestricted CD4 + helper T-lymphocytes and CD8 + cytotoxic T-lymphocytes. A predominantly type-1 helper T-lymphocyte response develops and leads to the secretion of cytokines, such as interleukin (IL)-2 and IFN-γ. These cytokines contribute to liver cell injury as well as to recovery from disease.
In patients with CHB, the peripheral cytotoxic T-lymphocyte response is usually weak or undetectable and narrow in focus. An activated humoral response develops, characterized by the production of IL-4, IL-5, and IL-10 secreted by type-2 helper T-lymphocytes; this response has been demonstrated to promote antibody production, rather than viral clearance. Low levels of intrahepatic HBV-specific cytotoxic T-lymphocyte have been detected in these patients and are probably responsible for the hepatic flares that occur in patients with chronic disease [72] [73] [74] . However, these activated cytotoxic T-lymphocytes are unable to clear HBV [75] .
What is emerging now is the recognition that, not only the adaptive [66, 76] , but also the innate immune response, are both required for control of viral replication. Innate immunity could account for a substantial part of the antiviral effort and effectiveness of the overall host immune response. For example, this has been recently demonstrated in vitro, where it has been shown that hepatocyte-derived cells [77] and non parenchymal cells (Kuppfer cells) [78] can mount an effective innate response to HBV infection with the production of IFN-β or IL-6, respectively, which in turn can control viral replication.
Host genetics and the outcomes of HBV infection
Several epidemiological factors such as age of infection, gender, coinfection with other hepatitis viruses and excessive alcohol use have all been implicated in affecting HBV persistence and eventual clinical outcome.
The first study to demonstrate that the host genetic background does strongly influence infection outcome came from Taiwan [79] . Furthermore, subsequent studies have demonstrated that genetic variants in IFN-γ, TNF-α, vitamin D receptor, oestrogen receptor-1 and several HLA loci were associated with CHB [80] [81] [82] [83] [84] . Similarly, HLA-DR 13 has been reported to have a protective effect against persistent HBV infection in different populations [84] [85] [86] . More recently, using a genome-wide association approach, Kamatani et al. [87] showed that genetic variants in the HLA-DP locus are significantly associated with the risk of persistent infection with HBV in Asian patients. The HLA-DP complexes are involved in antigen presentation and, interestingly, have been previously implicated to be predictive factors for antibody production following HBV vaccination [88] .
Such studies are shedding new light on the pathogenesis of CHB and could even facilitate the development of new therapies for treatment. In support of this notion, the recent identification of genetic variations in the IL-28B locus (type-III IFN-λ), which could highly significantly predict hepatitis C treatment-induced viral clearance [3, 89] , is particularly noteworthy. These recent findings should translate into genotype-based treatment decisions for individual patients with CHB.
Conclusions
After nearly 30 years of clinical research, safe and efficacious antiviral drugs with which to treat HBV infection are finally available; however, as their clinical use becomes more common and patient adherence remains low, the emergence of viral resistance to these drugs will undoubtedly increase. Control of these drug-resistant HBV mutants, will require the development of new drugs, including therapeutic vaccines and other biological response modifiers, in order to devise and implement more effective treatment strategies. This will become the next major challenge on the path to control and eventually eliminate HBV infection. Nevertheless, prospects for control of CHB infection have never been better, given the development of more sensitive and sophisticated diagnostic tests [90] , algorithms predicting longer term virological control [91] and the renewed impetus provided by immunization programmes [1] .
Sufficiently potent inhibition of HBV replication is now available to the clinician to prevent the development of drug resistance. If viral replication can be suppressed for a sufficient length of time, viral load will decrease to a level at which continued production of quasispecies with the potential to resist new drug treatments is no longer possible. As a consequence, indirect effects on other markers, such as HBsAg, and long-term control via HBsAg seroconversion might be achievable.
